safety

You have access
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent and Jilong Yang

Cancer Biology & Medicine June 2022, 19 (6) 910-930; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0270
You have access
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
Zhichao Liao, Ting Li, Chao Zhang, Xinyue Liu, Ruwei Xing, Sheng Teng, Yun Yang, Gang Zhao, Xu Bai, Jun Zhao and Jilong Yang

Cancer Biology & Medicine May 2020, 17 (2) 501-512; DOI: https://doi.org/10.20892/j.issn.2095-3941.2019.0397
You have access
Pemetrexed Monotherapy and Pemetrexed Plus Platinum Combination Therapy as Non-First-Line Treatments for Advanced Non-Small Cell Lung Cancer
Fang WANG, Gui-fang GUO, Hui-juan QIU, Xu-xian CHEN, Pi-li HU, Fei-fei ZHOU, Wen-zhuo HE, Bei ZHANG and Liang-ping XIA

Clinical Oncology and Cancer Research December 2011, 8 (4) 235-241; DOI: https://doi.org/10.1007/s11805-011-0587-3

Main menu